Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma.
Van Treeck BJ, Olave MC, Watkins RD, Lu H, Moreira RK, Mounajjed T, Johnson MJ, Smith CY, Ilyas SI, Tran NH, Jenkins SM, Reed KA, Smoot R, Mahipal A, Allende D, Graham RP. Van Treeck BJ, et al. Among authors: tran nh. HPB (Oxford). 2024 Apr 23:S1365-182X(24)01259-0. doi: 10.1016/j.hpb.2024.04.003. Online ahead of print. HPB (Oxford). 2024. PMID: 38705793
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.
Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. Ahn DH, et al. Among authors: tran nh. Invest New Drugs. 2022 Feb;40(1):134-141. doi: 10.1007/s10637-021-01170-x. Epub 2021 Aug 31. Invest New Drugs. 2022. PMID: 34463891 Clinical Trial.
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience.
Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. Gile JJ, et al. Among authors: tran nh. JCO Precis Oncol. 2021 Jul 28;5:PO.21.00064. doi: 10.1200/PO.21.00064. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34778691 Free PMC article.
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68 Ga-PSMA-11 PET Using Cyclotron-Produced 68 Ga.
Thompson SM, Suman G, Torbenson MS, Chen ZE, Jondal DE, Patra A, Ehman EC, Andrews JC, Fleming CJ, Welch BT, Kurup AN, Roberts LR, Watt KD, Truty MJ, Cleary SP, Smoot RL, Heimbach JK, Tran NH, Mahipal A, Yin J, Zemla T, Wang C, Fogarty Z, Jacobson M, Kemp BJ, Venkatesh SK, Johnson GB, Woodrum DA, Goenka AH. Thompson SM, et al. Among authors: tran nh. Hepatol Commun. 2022 May;6(5):1172-1185. doi: 10.1002/hep4.1861. Epub 2021 Nov 15. Hepatol Commun. 2022. PMID: 34783177 Free PMC article.
Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma.
Gile JJ, Wookey V, Zemla TJ, Shi Q, Jin Z, Alberts SR, McWilliams RR, Ma WW, Borad M, Bekaii-Saab TS, Tran NH, Mahipal A. Gile JJ, et al. Among authors: tran nh. Target Oncol. 2022 Sep;17(5):529-538. doi: 10.1007/s11523-022-00914-w. Epub 2022 Sep 2. Target Oncol. 2022. PMID: 36056231
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP, Merrell KW, Thiels CA, Hallemeier CL, Warner SG, Haddock MG, Grotz TE, Tran NH, Smoot RL, Ma WW, Cleary SP, McWilliams RR, Nagorney DM, Halfdanarson TR, Kendrick ML, Truty MJ. Abdelrahman AM, et al. Among authors: tran nh. J Natl Compr Canc Netw. 2022 Sep;20(9):1023-1032.e3. doi: 10.6004/jnccn.2022.7041. J Natl Compr Canc Netw. 2022. PMID: 36075389
222 results